Back to Search
CHARLES HICKS
Speech-Language Assistant
NPI: 1588531750Individual
Specialties, Licenses & Credentials
Speech-Language AssistantPrimary
Specialist/Technologist — Speech-Language Assistant
Code: 2355S0801X
SLPA16792(AZ)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (7)
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
PMID 14707788·J Acquir Immune Defic Syndr·2004
3-trial
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
PMID 14699460·Clin Infect Dis·2004
3-trial
Amprenavir: a review of its clinical potential in patients with HIV infection.
PMID 11152018·Drugs·2000
6-review
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
PMID 11073755·Clin Infect Dis·2000
6-review
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
PMID 10888979·Arch Intern Med·2000
8-other
Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
PMID 10868554·Clin Ther·2000
6-review
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
PMID 10647802·JAMA·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3910 S ALMA SCHOOL RD STE 1
CHANDLER, AZ 85248 - Phone
- (602) 291-9375
Quick Facts
- NPI
- 1588531750
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 7
Are you this provider?
Claim Your Profile